Symmetry Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Symmetry Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,202	Closed	-$214K	–	542
2023 Q4	$214K	Sell	2,202 -546	-20%	-$48.3K	0.01%	477
2023 Q3	$243K	Hold	2,748	–	–	0.01%	470
2023 Q2	$238K	Hold	2,748	–	–	0.01%	520
2023 Q1	$267K	Hold	2,748	–	–	0.01%	473
2022 Q4	$284K	Hold	2,748	–	–	0.02%	474
2022 Q3	$233K	Hold	2,748	–	–	0.02%	500
2022 Q2	$228K	Hold	2,748	–	–	0.02%	511
2022 Q1	$212K	Hold	2,748	–	–	0.01%	559
2021 Q4	$243K	Hold	2,748	–	–	0.02%	560
2021 Q3	$211K	Hold	2,748	–	–	0.01%	625
2021 Q2	$229K	Hold	2,748	–	–	0.02%	624
2021 Q1	$208K	Sell	2,748 -17	-0.6%	-$1.39K	0.01%	621
2020 Q4	$242K	Buy	2,765 +11	+0.4%	+$872	0.02%	558
2020 Q3	$210K	Buy	+2,754	New	+$279K	0.02%	560

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Symmetry Partners's BMRN Position: Q1 2024 in Review

Symmetry Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 2,202 shares — an estimated $214K sold.

Symmetry Partners first reported a position in BMRN in Q3 2020 and held it in 14 quarters. The position peaked at $284K in Q4 2022. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

Symmetry Partners reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Symmetry Partners sold 2,202 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $214K.
Symmetry Partners first reported a position in BioMarin Pharmaceuticals in Q3 2020 and held it in 14 quarters.
Symmetry Partners's BioMarin Pharmaceuticals position peaked at $284K in Q4 2022.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Symmetry Partners's 13F filing for Q1 2024, filed 2 Apr 2024.